IN8BIO, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
IN8bio, a $7.6M market-cap clinical-stage biotech, reported Q2 2026 cash of $17.96M (vs $27.1M at year-end 2025), with quarterly operating expenses of $4.9M ($2.5M R&D, $2.4M G&A). Net loss was $4.8M for Q2 2026 vs $5.1M in Q2 2025. The company advanced its DeltEx DRI glioblastoma program (published Phase 1 data showing median overall survival >19.5 months vs 13.2 months for standard-of-care) and INB-619 gamma-delta T cell engager platform (preclinical in vivo data expected H2 2026). Cash runway at current burn rate is approximately 3.6 years.
Why this rating
Routine quarterly disclosure. Company has sufficient cash (~18M) relative to quarterly burn (~5M) for 3–4 years' runway. Clinical milestones are positive but preclinical; no transformational event or financing disclosed. Relative to $7.6M market cap, cash position is solid but not game-changing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.